Apogee Therapeutics (NASDAQ:APGE) Rating Reiterated by Wedbush

Apogee Therapeutics (NASDAQ:APGEGet Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a report issued on Monday, RTT News reports. They currently have a $40.00 target price on the stock. Wedbush’s price target suggests a potential upside of 133.78% from the company’s current price.

Several other equities analysts have also issued reports on APGE. William Blair reissued an “outperform” rating and issued a $40.00 price target on shares of Apogee Therapeutics in a report on Monday, August 28th. TD Cowen assumed coverage on Apogee Therapeutics in a research report on Tuesday, August 8th. They set an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on Apogee Therapeutics in a research report on Tuesday, August 8th. They issued a “buy” rating and a $34.00 price objective for the company. Jefferies Financial Group began coverage on Apogee Therapeutics in a research note on Tuesday, August 8th. They set a “buy” rating and a $29.00 target price for the company. Finally, Guggenheim started coverage on shares of Apogee Therapeutics in a research note on Tuesday, August 8th. They issued a “buy” rating and a $29.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $34.40.

Read Our Latest Stock Report on APGE

Apogee Therapeutics Trading Up 5.1 %

NASDAQ:APGE opened at $17.11 on Monday. Apogee Therapeutics has a 1-year low of $14.19 and a 1-year high of $25.54. The firm has a 50-day moving average of $19.61.

Apogee Therapeutics (NASDAQ:APGEGet Free Report) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Research analysts anticipate that Apogee Therapeutics will post -2.22 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank bought a new position in shares of Apogee Therapeutics in the 3rd quarter valued at about $52,000. UBS Group AG acquired a new stake in Apogee Therapeutics in the 3rd quarter valued at about $76,000. Strs Ohio bought a new position in Apogee Therapeutics during the third quarter worth about $87,000. New York State Common Retirement Fund acquired a new position in Apogee Therapeutics during the third quarter worth approximately $90,000. Finally, California State Teachers Retirement System acquired a new position in Apogee Therapeutics during the third quarter worth approximately $92,000. 32.06% of the stock is owned by institutional investors.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

See Also

Analyst Recommendations for Apogee Therapeutics (NASDAQ:APGE)

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.